Influence of severe renal impairment on the pharmacokinetics of clazosentan

Journal of Clinical Pharmacology

Volumn 51, Issue 3, 2011, Pages 413-421

  Bruderer, Shirin ^a   Sasu, Boris ^b   Tsvitbaum, Nahum ^b   Dingemanse, Jasper ^a  

^a ACTELION PHARMACEUTICALS LTD   (Switzerland)

^b State Medical Sanitary Institution   (Moldova)

Author keywords

Clazosentan; endothelin; pharmacokinetics; renal impairment

Indexed keywords

CLAZOSENTAN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BODY MASS; CLINICAL ARTICLE; COMPARTMENT MODEL; CONTINUOUS INFUSION; CONTROLLED STUDY; CREATININE CLEARANCE; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; KIDNEY DISEASE; MALE; PHASE 1 CLINICAL TRIAL; STEADY STATE;

ADULT; DIOXANES; FEMALE; HALF-LIFE; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY FAILURE, CHRONIC; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MODELS, BIOLOGICAL; PYRIDINES; PYRIMIDINES; RECEPTOR, ENDOTHELIN A; RENAL INSUFFICIENCY; SEVERITY OF ILLNESS INDEX; SUBARACHNOID HEMORRHAGE; SULFONAMIDES; TETRAZOLES; VASOSPASM, INTRACRANIAL;

EID: 78650007764     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270010368975     Document Type: Article

References (19)

1. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332:411-415. (Pubitemid 18090241)
2. Stewart DJ, Levy RD, Cernacek P, Langleben D. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Ann Intern Med. 1991;114:464-469.
3. Masaoka H, Suzuki R, Hirata Y, Emori T, Marumo F, Hirakawa K. Raised plasma endothelin in aneurysmal subarachnoid haemorrhage. Lancet. 1989;2:1402. (Pubitemid 20003021)
4. Zuccarello M, Soattin GB, Lewis AL, et al. Prevention of subarachnoid hemorrhage-induced cerebral vasospasm by oral administration of endothelin receptor antagonists. J Neurosurg. 1996;84:503-507. (Pubitemid 26064559)
5. Foley PL, Caner HH, Kassell NF, Lee KS. Reversal of subarachnoid hemorrhage-induced vasoconstriction with an endothelin receptor antagonist. Neurosurgery. 1994;34:108-112.
6. Clozel M, Watanabe H. BQ-123, a peptidic endothelin ETA receptor antagonist, prevents the early cerebral vasospasm following subarachnoid hemorrhage after intracisternal but not intravenous injection. Life Sci. 1993;52:825-834.
7. Zimmermann M, Seifert V, Loffler BM, Stolke D, Stenzel W. Prevention of cerebral vasospasm after experimental subarachnoid hemorrhage by RO 47-0203, a newly developed orally active endothelin receptor antagonist. Neurosurgery. 1996;38:115-120. (Pubitemid 26002390)
8. Roux S, Breu V, Giller T, et al. Ro 61-1790, a new hydrosoluble endothelin antagonist: general pharmacology and effects on experimental cerebral vasospasm. J Pharmacol Exp Ther. 1997;283:1110-1118. (Pubitemid 28016483)
9. Vajkoczy P, Meyer B, Weidauer S, et al. Clazosentan (AXV-034343), a selective endothelin A receptor antagonist, in the prevention of cerebral vasospasm following severe aneurysmal subarachnoid hemorrhage: results of a randomized, double-blind, placebo-controlled multicenter Phase IIa study. J Neurosurg. 2005;103:9-17. (Pubitemid 43193928)
10. van Giersbergen PLM, Dingemanse J. Tolerability, pharmacokinetics, and pharmacodynamics of clazosentan, a parenteral endothelin receptor antagonist. Eur J Clin Pharmacol. 2007;63:151-158. (Pubitemid 46147056)
11. van Giersbergen PLM, Dingemanse J. Effect of gender on the tolerability, safety and pharmacokinetics of clazosentan following long-term infusion. Clin Drug Investig. 2007;27:797-802. (Pubitemid 47529295)
12. van Giersbergen PLM, Gunawardena KA, Dingemanse J. Influence of ethnic origin and sex on the pharmacokinetics of clazosentan. J Clin Pharmacol. 2007;47:1374-1380. (Pubitemid 47624597)
13. van Giersbergen PLM, Treiber A, Dingemanse J. In vitro and in vivo pharmacokinetic characteristics of clazosentan, an intravenous endothelin receptor antagonist, in humans. Int J Clin Pharmacol Ther. 2009;47:169-177.
14. Guidance for Industry Pharmacokinetics in Patients with Impaired Renal Function Study Design, Data Analysis, and Impact on Dosing and Labeling. Silver Spring, Md: FDA; 1998.
15. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16: 31-41.
16. Binet I, Wallnöfer A, Weber C, Jones R, Thiel G. Renal hemodynamics and pharmacokinetics of bosentan with and without cyclosporine A. Kidney Int. 2000;57:224-231. (Pubitemid 30227769)
17. Van Giersbergen PLM, Bodin F, Dingemanse J. Cyclosporine increases the exposure to tezosentan, an intravenous dual endothelin receptor antagonist. Eur J Clin Pharmacol. 2002;58:243-245. (Pubitemid 34827852)
18. Treiber A, Schneiter R, Delahaye S, and Clozel M. Inhibition of organic anion transporting polypeptide-mediated hepatic uptake is the major determinant in the pharmacokinetic interaction between bosentan and cyclosporin A in the rat. J Pharmacol Exp Ther. 2004;308:1121-1129. (Pubitemid 38263989)
19. Benet LZ, Hoener BA. Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther. 2002;71:115-121. (Pubitemid 34271114)